A Phase I Multiple Ascending Dose Study of ASLAN002 (BMS 777607) in Subjects With Advanced or Metastatic Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2017
At a glance
- Drugs BMS 777607 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors ASLAN Pharmaceuticals
- 15 Feb 2017 Results published in an ASLAN Pharmaceuticals media release.
- 15 Feb 2017 According to an ASLAN Pharmaceuticals media release, new data from this phase 1 study of ASLAN002 (BMS777607) published in Science Translational Medicine journal.
- 23 Jan 2017 Status changed from active, no longer recruiting to completed.